Archive: March 11 2021
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Experimental safety switch reduces severity of CAR-T immunotherapy-related side ...
UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.
Bispecific Antibodies Could Be the Next Big Advance in Oncology
Human monoclonal antibody therapies are among the fastest growing categories in the cancer pipeline, with more than 570 agents in clinical development. Now, a new type of antibody-based therapy may overcome the limitations of monoclonal antibodies, and it has the potential to disrupt the current treatment paradigm in oncology.
The Growing Role of Monoclonal Antibodies in Relapsed/Refractory Follicular Lymp...
Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.
Immunotherapy Is on the Cusp of Major Breakthroughs in Multiple Myeloma
Just a decade ago, immune therapy for multiple myeloma barely existed as an idea. Since then, immune therapy has evolved rapidly and the field is on the verge of major improvements in outcomes.
Brentuximab Vedotin Plus Chemotherapy Works as a Primary Option for Hodgkin Lymp...
Pierluigi Porcu, MD, explained how the combination of brentuximab vedotin plus chemotherapy works in in frontline setting of Hodgkin lymphoma during a virtual Targeted Oncology Case-Based Roundtable event.
Zelenoleucel in Phase 2 Study of Patients With AML
The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.